Peer-Reviewed Published Studies
Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life
in Chronic Lung Disease (Rubio, 2019)
Sample†
ALL (COPD+ILD)
Number of patients sampled (n=3,471)
Sample: Patients with a diagnosis of either COPD or ILD (including emphysema, chronic bronchitis, pulmonary fibrosis, bronchiectasis, sarcoidosis, asbestosis, or unspecified interstitial lung disease).
Key Outcomes
QoL measurements
at 3, 6 and 12-months post-treatment to assess symptoms, mental health status and functional status. using CCQ
Result
3-months:
73.8% improved QoL
17.4% no change/decline in QoL
91.2% total improved or did not decline
6-months:
70.5% improved QoL
18.8% no change/decline in QoL
89.3% total improved or did not decline
12-months:
61.7% improved QoL
22.8% no change/decline in QoL
84.5% total improved or did not decline
Publication Source
Rubio MM.Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease.J Clin Res Med.2019;2(4):1-8
https://centersforrespiratoryhealth.com/2019beyondtheordinary/
COPD ONLY
Number of patients sampled (n=2,813)
Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.
QoL measurements
at 3, 6 and 12-months post-treatment to assess symptoms, mental health status and functional status using CCQ.
3-months:
75% improved QoL
16.6% no change/decline in QoL
91.6% total improved or did not decline
6-months:
72.6% improved QoL
18.3% no change/decline in QoL
90.9% total improved or did not decline
12-months:
64.1% improved QoL
22.5% no change/decline in QoL
86.6% total improved or did not decline
https://centersforrespiratoryhealth.com/2019beyondtheordinary/
ILD ONLY
Number of patients sampled (n=567)
Sample: Patients with a diagnosis of interstitial lung disease (pulmonary fibrosis, sarcoidosis, asbestosis or unspecified interstitial lung disease).
QoL measurements
at 3, 6 and 12-months post-treatment to assess symptoms, mental health status and functional status using CCQ.
3-months:
66.2% improved QoL
21.8% no change/decline in QoL
88.0% total improved or did not decline
6-months:
59.4% improved QoL
21.3% no change/decline in QoL
80.7% total improved or did not decline
12-months:
47.6% improved QoL
24.4% no change/decline in QoL
72.0% total improved or did not decline
https://centersforrespiratoryhealth.com/2019beyondtheordinary/
† All samples are random sub-groups from the overall pool of patients treated at H-Cyte. Citation: Melissa M. Rubio (2019) Beyond the Ordinary: The Effect of Cellular Therapy on Quality of Life in Chronic Lung Disease. J Clin Res Med Volume 2(4): 1–8.
Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy (Rubio, 2021).
Sample†
COPD ONLY
Number of patients sampled = 150
Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.
Key Outcomes
QoL measurements
at 3 months post-treatment to assess symptoms, mental health status and functional status using CCQ.
FEV1 measurements
at 3 months post-treatment.
Result
3-months:
64.0% improved QoL
20.0% had no change/decline in QoL
84.0% total improved or did not decline
3-months:
23.3% improved FEV1 by at least 15% over their baseline
3-months:
7.2% FEV1 average increase from participants’ baseline
Publication Source
Rubio MM. Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy. J Reg Med Biol Res. 2021;2(1):1-11.
https://centersforrespiratoryhealth.com/2021fev1/
COPD ONLY
Number of patients sampled = 131
Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.
QoL measurements
at least 12 months post-treatment to assess symptoms, mental health status and functional status using CCQ.
FEV1 measurements
at least 12 months post-treatment
12-months:
67.2% improved QoL
8.4% had no change/decline in QoL
75.6% total improved or did not decline
12-months:
29% improved FEV1 by at least
15% over their baseline FEV1.
12-months:
6.88% FEV1 average increase from participants’ baseline
† All samples are random sub-groups from the overall pool of patients treated at H-Cyte. Citation: Rubio MM. Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy. J Reg Med Biol Res. 2021;2(1):1-11.
Platelet Rich Plasma- Platelet Concentrate Therapy in COPD: An Observational Cohort Study (Rubio, 2021).
Sample†
COPD ONLY
Number of patients sampled = 150
Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.
Key Outcomes
FEV1 measurements
at 3 months post-treatment.
Result
3-months:
67.3% improved or no decline from baseline for FEV1
3-months:
7.83% FEV1 average increase from participants’ baseline
3-months:
12.42% FEV1 average increase from Participants’ baseline (GOLD stage 4)
Publication Source
https://centersforrespiratoryhealth.com/2021prppcincopd/
COPD ONLY
Number of patients sampled = 419
Sample: Patients with a diagnosis of COPD (chronic bronchitis, emphysema, bronchiectasis, or a combination of the above) in all stages of disease severity.
QoL measurements
at 3, 6 and 12-months post-treatment to assess symptoms, mental health status and functional status using CCQ.
3-months:
65.2% improved QoL
17.9% no change/decline in QoL
83.1% total improved or did not decline
6-months:
65.1% improved QoL
13.2% no change/decline in QoL
78.3% total improved or did not decline
12-months:
61.0% improved QoL
12.2% no change/decline in QoL
73.2% total improved or did not decline
https://centersforrespiratoryhealth.com/2021prppcincopd/
† All samples are random sub-groups from the overall pool of patients treated at H-Cyte. Citation:Rubio MM, et al. Platelet Rich Plasma- Platelet Concentrate Therapy in COPD: An Observational Cohort Study. J Reg Med Biol Res. 2021;2(2):1-10